(GSK) GlaxoSmithKline - Overview
Sector: Healthcare | Industry: Drug Manufacturers - General | Exchange: NYSE (USA) | Market Cap: 103.404m USD | Total Return: 37% in 12m
Avg Turnover: 187M
EPS Trend: 95.3%
Qual. Beats: 0
Rev. Trend: 96.4%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
GSK plc is a global biopharmaceutical company headquartered in London, specializing in the development and manufacture of vaccines, specialty medicines, and general medicines. The firm operates through two primary segments: Commercial Operations and Total R&D, focusing on therapeutic areas such as oncology, immunology, HIV, and respiratory diseases. Following the demerger of its consumer healthcare business, the company’s business model is now centered on high-margin innovation and high-volume vaccine distribution.
The company’s portfolio includes preventative vaccines for shingles, RSV, and meningitis, alongside general medicines for chronic conditions like asthma and COPD. In the pharmaceutical sector, long-term growth is heavily dependent on R&D pipelines and the successful navigation of patent cycles for proprietary small-molecule therapies. GSK maintains strategic alliances, such as its collaboration with CureVac, to advance mRNA technology and address unmet needs in infectious diseases.
Investors can further examine the companys valuation metrics and dividend history on ValueRay. GSK remains a major player in the global healthcare market, leveraging a history dating back to 1715 to maintain its competitive position in the United States and international markets.
- Shingrix and Arexvy vaccine sales drive core revenue growth and market share
- Resolution of Zantac litigation liabilities reduces long-term legal and financial risk
- HIV portfolio performance and ViiV Healthcare margins sustain consistent cash flow
- Late-stage R&D pipeline execution determines long-term specialty medicine revenue potential
- US and EU regulatory approvals for oncology drugs impact future top-line expansion
| Net Income: 5.83b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 2.58 > 1.0 |
| NWC/Revenue: -18.78% < 20% (prev -11.24%; Δ -7.54% < -1%) |
| CFO/TA 0.10 > 3% & CFO 8.30b > Net Income 5.83b |
| Net Debt (21.4b) to EBITDA (11.3b): 1.90 < 3 |
| Current Ratio: 0.79 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.04b) vs 12m ago -1.52% < -2% |
| Gross Margin: 72.68% > 18% (prev 0.71%; Δ 7.20k% > 0.5%) |
| Asset Turnover: 40.65% > 50% (prev 40.24%; Δ 0.42% > 0%) |
| Interest Coverage Ratio: 11.75 > 6 (EBITDA TTM 11.3b / Interest Expense TTM 692.0m) |
| A: -0.07 (Total Current Assets 23.4b - Total Current Liabilities 29.6b) / Total Assets 82.9b |
| B: 0.18 (Retained Earnings 15.3b / Total Assets 82.9b) |
| C: 0.10 (EBIT TTM 8.13b / Avg Total Assets 80.6b) |
| D: 0.32 (Book Value of Equity 18.9b / Total Liabilities 59.9b) |
| Altman-Z'' = 1.12 = BB |
| DSRI: 1.04 (Receivables 10.5b/9.68b, Revenue 32.8b/31.5b) |
| GMI: 0.98 (GM 72.68% / 71.41%) |
| AQI: 1.04 (AQ_t 0.56 / AQ_t-1 0.54) |
| SGI: 1.04 (Revenue 32.8b / 31.5b) |
| TATA: -0.03 (NI 5.83b - CFO 8.30b) / TA 82.9b) |
| Beneish M = -2.99 (Cap -4..+1) = A |
As of May 24, 2026, the stock is trading at USD 51.53 with a total of 1,875,223 shares traded.
Over the past week, the price has changed by +3.44%,
over one month by -6.91%,
over three months by -12.51% and
over the past year by +36.96%.
GlaxoSmithKline has received a consensus analysts rating of 2.88. Therefore, it is recommended to hold GSK.
- StrongBuy: 1
- Buy: 0
- Hold: 5
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 57.7 | 11.9% |
P/E Trailing = 13.5249
P/E Forward = 10.7181
P/S = 3.1545
P/B = 4.3242
P/EG = 0.4986
Revenue TTM = 32.8b GBP
EBIT TTM = 8.13b GBP
EBITDA TTM = 11.3b GBP
Long Term Debt = 14.0b GBP (from longTermDebt, last fiscal year)
Short Term Debt = 6.65b GBP (from shortTermDebt, last quarter)
Debt = 26.0b GBP (from shortLongTermDebtTotal, last quarter) + Leases 830.0m
Net Debt = 21.4b GBP (calculated: Debt 26.0b - CCE 4.54b)
Enterprise Value = 98.4b GBP (76.9b + Debt 26.0b - CCE 4.54b)
Interest Coverage Ratio = 11.75 (Ebit TTM 8.13b / Interest Expense TTM 692.0m)
EV/FCF = 15.77x (Enterprise Value 98.4b / FCF TTM 6.24b)
FCF Yield = 6.34% (FCF TTM 6.24b / Enterprise Value 98.4b)
FCF Margin = 19.02% (FCF TTM 6.24b / Revenue TTM 32.8b)
Net Margin = 17.78% (Net Income TTM 5.83b / Revenue TTM 32.8b)
Gross Margin = 72.68% ((Revenue TTM 32.8b - Cost of Revenue TTM 8.96b) / Revenue TTM)
Gross Margin QoQ = 75.42% (prev 69.17%)
Tobins Q-Ratio = 1.19 (Enterprise Value 98.4b / Total Assets 82.9b)
Interest Expense / Debt = 2.67% (Interest Expense 692.0m / Debt 26.0b)
Taxrate = 14.23% (305.0m / 2.14b)
NOPAT = 6.97b (EBIT 8.13b * (1 - 14.23%))
Current Ratio = 0.79 (Total Current Assets 23.4b / Total Current Liabilities 29.6b)
Debt / Equity = 1.10 (Debt 26.0b / totalStockholderEquity, last quarter 23.5b)
Debt / EBITDA = 1.90 (Net Debt 21.4b / EBITDA 11.3b)
Debt / FCF = 3.43 (Net Debt 21.4b / FCF TTM 6.24b)
Total Stockholder Equity = 20.5b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.23% (Net Income 5.83b / Total Assets 82.9b)
RoE = 28.47% (Net Income TTM 5.83b / Total Stockholder Equity 20.5b)
RoCE = 23.57% (EBIT 8.13b / Capital Employed (Equity 20.5b + L.T.Debt 14.0b))
RoIC = 11.62% (NOPAT 6.97b / Invested Capital 60.0b)
WACC = 5.68% (E(76.9b)/V(103b) * Re(6.82%) + D(26.0b)/V(103b) * Rd(2.67%) * (1-Tc(0.14)))
Discount Rate = 6.82% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -42.22 | Cagr: -0.47%
[DCF] Terminal Value 77.97% ; FCFF base≈5.29b ; Y1≈6.07b ; Y5≈8.93b
[DCF] Fair Price = 56.27 (EV 134b - Net Debt 21.4b = Equity 113b / Shares 2.01b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 95.31 | EPS CAGR: 8.67% | SUE: 0.81 | # QB: 0
Revenue Correlation: 96.40 | Revenue CAGR: 3.79% | SUE: 0.01 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.24 | Chg30d=-3.27% | Revisions=+33% | Analysts=2
EPS next Quarter (2026-09-30): EPS=1.44 | Chg30d=-2.44% | Revisions=+33% | Analysts=2
EPS current Year (2026-12-31): EPS=4.82 | Chg30d=+0.31% | Revisions=+14% | GrowthEPS=+2.4% | GrowthRev=+3.4%
EPS next Year (2027-12-31): EPS=5.22 | Chg30d=+1.08% | Revisions=+14% | GrowthEPS=+8.2% | GrowthRev=+4.9%
[Analyst] Revisions Ratio: +33%